2000•The Journal of Clinical PsychiatryOpen access

Venlafaxine Versus Sertraline for Major Depressive Disorder

Thomas N. Wise, Michael J. Sheridan

Open full text 2 citations

Abstract

Article AbstractLetter to the Editor Sir: The recent report by Mehtonen et al. concludes that venlafaxine is superior in efficacy to sertraline in depressed psychiatric outpatients. A number of factors within the study suggest that their conclusion needs to be tempered. While the overall rates of discontinuation may have been comparable, the proportion of adverse advents in the venlafaxine cohort was twice that of the sertraline cohort (16% vs. 7%), and of all patients who discontinued medication treatment over the course of the study, the proportion of those discontinuing therapy in the first week with venlafaxine was also twice that of the sertraline group (8/16 = 50% vs. 3/12 = 25%, respectively). The proportion of adverse advents for those discontinuing therapy in the first week of venlafaxine treatment was slightly greater than twice that for the sertraline group (6/8 = 75% vs. 1/3 = 33%, respectively).

Open-access reader

About this research paper

What this paper is about

Article AbstractLetter to the Editor Sir: The recent report by Mehtonen et al. concludes that venlafaxine is superior in efficacy to sertraline in depressed psychiatric outpatients. A number of factors within the study suggest that their conclusion needs to be tempered. While the overall rates of discontinuation may have been comparable, the proportion of adverse advents in the venlafaxine cohort was twice that of the sertraline cohort (16% vs. 7%), and of all patients who discontinued medication treatment over the course of the study, the proportion of those discontinuing therapy in the first week with venlafaxine was also twice that of the sertraline group (8/16 = 50% vs. 3/12 = 25%, respectively). The proportion of adverse advents for those discontinuing therapy in the first week of venlafaxine treatment was slightly greater than twice that for the sertraline group (6/8 = 75% vs. 1/3 = 33%, respectively).

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Article AbstractLetter to the Editor Sir: The recent report by Mehtonen et al. concludes that venlafaxine is superior in efficacy to sertraline in depressed psychiatric outpatients. A number of factors within the study suggest that their conclusion needs to be tempered. While the overall rates of discontinuation may have been comparable, the proportion of adverse advents in the venlafaxine cohort was twice that of the sertraline cohort (16% vs. 7%), and of all patients who discontinued medication treatment over the course of the study, the proportion of those discontinuing therapy in the first week with venlafaxine was also twice that of the sertraline group (8/16 = 50% vs. 3/12 = 25%, respectively). The proportion of adverse advents for those discontinuing therapy in the first week of venlafaxine treatment was slightly greater than twice that for the sertraline group (6/8 = 75% vs. 1/3 = 33%, respectively).

Key concepts: Sertraline, Venlafaxine, Discontinuation, Major depressive disorder, Medicine, Cohort, Psychiatry, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Venlafaxine Versus Sertraline for Major Depressive Disorder — Research Paper | ScholarLens